- Home
- SMMT vs GMAB Comparison
SMMT vs GMAB Comparison
Compare SMMT & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMMT
- GMAB
- Stock Information
- Founded
- SMMT 2003
- GMAB 1999
- Country
- SMMT United States
- GMAB Denmark
- Employees
- SMMT N/A
- GMAB N/A
- Industry
- SMMT Biotechnology: Pharmaceutical Preparations
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- SMMT Health Care
- GMAB Health Care
- Exchange
- SMMT Nasdaq
- GMAB Nasdaq
- Market Cap
- SMMT 14.5B
- GMAB 15.0B
- IPO Year
- SMMT N/A
- GMAB N/A
- Fundamental
- Price
- SMMT $18.31
- GMAB $20.59
- Analyst Decision
- SMMT Strong Buy
- GMAB Buy
- Analyst Count
- SMMT 4
- GMAB 8
- Target Price
- SMMT $34.75
- GMAB $43.00
- AVG Volume (30 Days)
- SMMT 2.1M
- GMAB 1.5M
- Earning Date
- SMMT 10-30-2024
- GMAB 11-06-2024
- Dividend Yield
- SMMT N/A
- GMAB N/A
- EPS Growth
- SMMT N/A
- GMAB 14.35
- EPS
- SMMT N/A
- GMAB 10.80
- Revenue
- SMMT N/A
- GMAB $2,967,926,227.00
- Revenue This Year
- SMMT N/A
- GMAB $30.31
- Revenue Next Year
- SMMT N/A
- GMAB $16.49
- P/E Ratio
- SMMT N/A
- GMAB $18.52
- Revenue Growth
- SMMT N/A
- GMAB 17.75
- 52 Week Low
- SMMT $1.88
- GMAB $20.50
- 52 Week High
- SMMT $33.89
- GMAB $32.89
- Technical
- Relative Strength Index (RSI)
- SMMT 41.16
- GMAB 25.31
- Support Level
- SMMT $19.01
- GMAB $21.90
- Resistance Level
- SMMT $22.53
- GMAB $23.47
- Average True Range (ATR)
- SMMT 1.45
- GMAB 0.45
- MACD
- SMMT -0.21
- GMAB -0.12
- Stochastic Oscillator
- SMMT 4.85
- GMAB 3.03
About SMMT Summit Therapeutics Inc.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.